Athenex Announces US FDA Allowance of the Investigation New Drug Application of Oradoxel, the Proprietary Oral Form of Docetaxel

BUFFALO, N.Y. and HONG KONG, Jan. 25, 2016 -- (Healthcare Sales & Marketing Network) -- Athenex, Inc. announced today that it has received United States Food and Drug Administration (US FDA) allowance to proceed in the clinic with its proprietary oral for... Biopharmaceuticals, Oncology, FDAAthenex, Docetaxel, Orascovery
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news